Page 959«..1020..958959960961..970980..»

Confused About Antigen Testing For COVID-19? Here’s How It Differs From Antibody Testing – Yahoo Lifestyle

Posted: June 24, 2020 at 9:47 am

Shot of a young woman wearing a mask and suffering from throat pain in a doctor's office

The novel coronavirus has added a lot of terms to our collective vocabulary. The latest is antigens, and though these proteins may sound similar to antibodies - and both will be key to test as doctors learn more about COVID-19 - they actually play very different roles in the body and the course of the disease. POPSUGAR asked experts for a quick breakdown of these two terms and what they mean for the strategy moving forward.

Contrary to what it might sound like, antibodies actually protect your body! Your immune system produces these little Y-shaped proteins to defend you against invader cells (pathogens). "An antibody is the immunoglobulin (protein) produced by the immune system," Habib Sadeghi, DO, a physician and integrative medicine specialist in Los Angeles, told POPSUGAR.

Fun fact: antibodies are produced by certain lymphocytes. A doctor can check your antibody levels in your blood. For COVID-19, "doctors look for two kinds of antibodies to SARS CoV-2 to determine exposure: IgM antibodies that develop early in an infection and IgG antibodies that appear after levels start to drop about four weeks in," said Dr. Sadeghi. The latter would in theory allow you to develop some level of long-term immunity, but experts still aren't sure if that's the case.

Related: Study Says Shutdowns Put in Place Avoided 60 Million More Coronavirus Infections in the US

Antigens are not produced by the body. "An antigen is any substance that induces a response from the immune system," Dr. Sadeghi explained. This can range from a toxin to simply a foreign substance. Remember the pathogens we just mentioned? Those invader cells? Antigens are part of pathogens - the part that triggers the antibodies to spring into action.

From there, "an antibody is capable of binding with the antigen and neutralizing it," Dr. Sadeghi said. This is typically how your body fights off an infection.

Related: Why You Should Take Symptoms of COVID-19 Seriously, Even If You're Not Running a Fever

Story continues

Antigen tests are the latest offering in the fight against COVID-19, designed to help manage the large number of tests needed to detect active cases. Antigen testing is cheaper than nasal swab testing, and blood results come back faster.

"The antigen test looks for actual pieces of protein of the virus itself, where the antibody test looks for evidence of a person's immune system response to being infected," William Kimbrough, MD, of One Medical, told POPSUGAR. "This means that the antigen test is identifying people with active infections (similar to what the more broadly available PCR swabs do), where the antibody tests look for people who have been previously infected."

Your doctor can help you determine which test is right for you. Just remember: a positive result on the antibody test does not necessarily mean you have immunity, so please, keep social distancing and following CDC guidelines until there's a safe and effective vaccine.

POPSUGAR aims to give you the most accurate and up-to-date information about the coronavirus, but details and recommendations about this pandemic may have changed since publication. For the latest information on COVID-19, please check out resources from the WHO, CDC, and local public health departments.

Originally posted here:
Confused About Antigen Testing For COVID-19? Here's How It Differs From Antibody Testing - Yahoo Lifestyle

Posted in Integrative Medicine | Comments Off on Confused About Antigen Testing For COVID-19? Here’s How It Differs From Antibody Testing – Yahoo Lifestyle

What Is the Most Vital Part of an Effective Psychedelic Treatment? – Yahoo Finance

Posted: June 24, 2020 at 9:47 am

Whitefish, Montana--(Newsfile Corp. - June 24, 2020) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announces an article discussing psychedelic treatment, aftercare, and Mindleap Health's innovative approach to the practice.

Image 1: Mindleap Health

To view an enhanced version of Image 1, please visit:https://orders.newsfilecorp.com/files/6612/58428_8da51df83422581c_001full.jpg

Millions of people have had a psychedelic experience at some point in their life and with new FDA approved medicines and regulatory changes millions more will soon be able to as well. However, without support, it can be challenging to understand and integrate these experiences.

Psychedelic substances are not magic bullets, they are only one tool in the toolbelt of transformational healing and expansion of consciousness. Psychedelics can show people the way and illuminate the pathway towards better mental wellbeing but each person using them needs to be willing to do the work and have the commitment to actually change.

Psychedelic integration is designed to help people plan, prepare, and make sense of psychedelic experiences. Individuals who have participated in a therapeutic psychedelic treatment can benefit from a more comprehensive interpretation of their experience.

Click to hear Rick Doblin, founder of MAPS, share what the ideal integrative process looks like after taking a psychedelic and how to create the conditions to have the most therapeutic experience as possible.

Cannot view this video? Visit:https://www.youtube.com/watch?v=qwEmZW7H05g

Psychedelic Therapies will revolutionize mental health

MDMA as a treatment for post-traumatic stress disorder is in Phase 3 clinical trial and is expected to be approved very soon to treat the over 300 million people affected with the condition. Psilocybin for depressive disorders has two drugs in Phase 2 with patient populations over 322 million. All of these treatments are being fast-tracked by the FDA and once approved there will be a major need for a convenient and confidential integration ( psychedelic aftercare ) solution. Currently, there are 90+ psychedelic clinics but that number is growing with companies expanding to be able to meet the upcoming demand.

Mindleap Health: At the Convergence of Tech, Mental Health, and Science

Story continues

Image 2: Mindleap Health

To view an enhanced version of Image 2, please visit:https://media.zenfs.com/en-us/newsfile_64/325a0daf431fbc791dc0ca421617d222

Mindleap Health is at the forefront of this industry with its digital telehealth platform focused on the psychedelic therapy industry. Mindleap has recognized that there is an unmet need for people to access psychedelic integration specialists and is creating the world's first platform focusing on psychedelic aftercare.

The company's unique strategy was re-affirmed when it was acquired last week by Mydecine Innovations Group (CSE: MYCO) (OTC Pink: MYCOF) a life sciences company focused on the development and commercialization of products and services that contribute to improved health and wellbeing with a specific focus on psychedelic medicine.

The tools Mindleap is building are the first of their kind to allow the patient to monitor, record, and track their mood and habits (both positive and negative) along with providing access to modern health services, namely integrated coaching to translate psychedelic experiences into positive change.

The system is completely secure and compliant with HIPAA and GDPR mandates and is being developed by a world-class development team with a proven track record.

Finally, Digital Mental Healthcare

As a society, we are becoming more familiar with digital healthcare. Electronic medical records are now the norm. The Covid-19 pandemic has resulted in more usage of video visits to doctors as people sheltered in place to prevent virus spread. A crisis being a catalyst is certainly unfortunate, but it did just make e-visits more mainstream as doctors and patients alike embraced social distancing.

Apropos, already valued at $31.46 billion in 2018, the global telemedicine market is expected to grow at a 19.3% rate by 2025, indicating that adoption is only going to keep accelerating.

Mindleap's comprehensive platform, expected to launch at the end of summer, includes video visits, appointment scheduling and payment solutions.

Mindleap is also capitalizing on the world's love of digital technologies, such as smartphones and connected wearable devices, in a newer science dubbed digital phenotyping. By passively collecting data (e.g. sleep patterns, exercise, social patterns), outcomes can be predicted using Artificial Intelligence and Machine Learning. This information subsequently helps healthcare providers optimize support.

Image 3: The Mindleap App

To view an enhanced version of Image 3, please visit:https://orders.newsfilecorp.com/files/6612/58428_8da51df83422581c_004full.jpg

Image 4: The Mindleap App

To view an enhanced version of Image 4, please visit:https://orders.newsfilecorp.com/files/6612/58428_8da51df83422581c_005full.jpg

It is the epitome of the purpose of Big Data to anonymously help the greater cause by aggregating massive amounts of info. It's very valuable from both financial and humanitarian perspectives.

The market opportunity as a first mover is tremendous, to say the least. There are more than 577,000 mental health professionals and over 13,000 behavioral health clinics in the U.S. to treat the more than 45 million Americans that have a mental illness.

To put this market opportunity into perspective, consider Livongo. The company has made a splash on Wall Street ($7.4 billion market cap) with an application connecting diabetics to physicians with the strategy that better engagement will promote better health. There are fewer diabetics (~34 million) in the U.S. than people with mental illness.

We're at a Tipping Point

Thankfully, awareness is growing about the very real medicinal usefulness of psilocybin and other psychedelics. Indeed, they remain illegal as Schedule I drugs currently, but positions are beginning to soften to encourage clinical research. Oakland and Denver have already decriminalized magic mushrooms and over 100 other cities are considering similar action.

Leading research organizations, including Johns Hopkins, have dedicated millions of dollars to study psychedelics, which will only help create tailwinds with every positive development.

The next logical progression is providing patients with the best support possible to help them achieve meaningful changes to their quality of life. That's exactly what Mindleap Health - and now Mydecine Innovations Group - is bringing to the table by changing the shape of the aftercare model.

Click here to read the full story:

What is the Most Vital Part of an Effective Psychedelic Treatment?

Mindleap Health Company Contact:

Nik Vassev

Founder & CEO

nik@mindleap.health

https://mindleap.health/

About CFN Enterprises Inc.

CFN Enterprises Inc. (OTCQB: CNFN) is a digital media and ecommerce company focused on advancing businesses and brands in highly regulated emerging industries across the globe. CFN connects investors with new market opportunities while helping consumers find innovative products that enhance their lives. Learn more at http://www.cfnenterprisesinc.com.

CFN Enterprises Inc. Media Contact:

CFN Enterprises Inc.+001 (833) 420-CNFN investors@cfnenterprisesinc.com

FORWARD-LOOKING STATEMENT

Use of Forward-looking Statements

This press release may contain forward-looking statements from CFN Enterprises Inc. within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when CFN Enterprises Inc. describes the potential acquisition of BarNone assets and the related benefits, its pursuit of M&A opportunities, growth in CBD sales and spending on affiliate marketing, and uses other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, CFN Enterprises Inc. is using forward-looking statements. These forward-looking statements are based on the current expectations of the management of CFN Enterprises Inc. only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial markets; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products and services; or, loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of CFN Enterprises Inc. to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, CFN Enterprises Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting CFN Enterprises Inc., reference is made to CFN Enterprises Inc.'s reports filed from time to time with the Securities and Exchange Commission.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/58428

View original post here:
What Is the Most Vital Part of an Effective Psychedelic Treatment? - Yahoo Finance

Posted in Integrative Medicine | Comments Off on What Is the Most Vital Part of an Effective Psychedelic Treatment? – Yahoo Finance

Teens’ technology use and mental health: New report from the Connected Learning Lab provides insight into Youth Connections for Wellbeing – PR Web

Posted: June 24, 2020 at 9:47 am

We found that misplaced fears are deflecting attention from other real concerns, resulting in missed opportunities for leveraging technology and online communication to address adolescent mental health problems.

IRVINE, Calif. (PRWEB) June 23, 2020

With or without physical separation due to COVID-19, youth are using social media to connect and support each other, according to a report released today. Three leading researchers have just published Youth Connections for Wellbeing, an integrative review paper that illuminates how teens support each other through digital media during times of stress and isolation.

Leveraging their expertise across the fields of cultural anthropology, developmental psychology, and clinical psychology, scholars Mimi Ito, Candice Odgers, and Stephen Schueller discuss the potential of digital media to support youth wellbeing.

The work underlying the paper was completed prior to the COVID-19 global pandemic. The physical isolation that has resulted from shelter-in-place orders has yielded a seismic shift, making it even more critical to understand and leverage technology in a way that benefits youth.

The position paper summarizes current knowledge and redirects the conversation about adolescent social media use and wellbeing in three ways that are particularly relevant today:

1. Refocusing the debate over the relationship between youth social media use and wellbeing to reflect existing evidence, varied youth perspectives and backgrounds.

2. Identifying teen vulnerabilities and assets that may influence problematic and healthy social media engagement.

3. Suggesting opportunities where youth social engagement might mitigate vulnerabilities and leverage assets.

In the position paper Ito, Odgers, and Schueller highlight the need to move beyond the simple question of whether more time spent using social media causes mental health problems in adolescents. Instead, people should consider the specific forms of social media engagement that amplify or mitigate mental health risks for different adolescents. The team integrates findings from existing large-scale reviews, the voices of youth who have grown up on social media, and a systematic review of digital mental health apps available for youth.

The team finds that adolescents online risks often mirror offline vulnerabilities. They note that it is particularly important for messages, interventions, and strategies to be targeted and tailored to the most vulnerable youth and those underserved by traditional mental health services.

A number of relevant findings, opportunities, and benefits are outlined in the paper, including:

For example, one student interviewed shared how they experienced a supportive community online, saying: I think a lot of my mutuals on Instagram, they're very open to being emotionally vulnerable on Instagram, so they'll actually say, I'm not doing fine. I like it because it's a very nice community, just spreading love whether it be through comments or someone will actually say through messages like, Are you okay?

A freshman adjusting to life away from family shared how online connections made her feel close to them: My mother just started using Messenger. I taught her how to use it. And so she texts me here and there. She's like, Good morning, or, How are you doing?, and then we FaceTime. Then my siblings, we use Instagram because that's where we're mostly at. We send each other videos and memes, and then we kind of comment just to make our day.

Given the rising rates of mental health concerns among young people in the U.S., Ito, Odgers, and Schueller encourage a sense of urgency in focusing research, investment, and public attention on how digital spaces and tools can be better designed and used to support youth's mental health.

The paper, which was supported by Pivotal Ventures (https://www.pivotalventures.org/), a Melinda Gates Company, was published by the Connected Learning Lab at the University of California, Irvine, and is available at https://youthwellbeing.online/ReportRelease.

About the Authors

Mimi Ito is a learning scientist and a cultural anthropologist of technology use, examining children and youths changing relationships to media and communications. She is Director of the Connected Learning Lab, Professor in Residence and John D. and Catherine T. MacArthur Foundation Chair in Digital Media and Learning at the University of California, Irvine.

Candice Odgers is a developmental psychologist who studies adolescent mental health and how digital technologies can be leveraged to understand and support wellbeing. She is the Co-Director of the Child and Brain Development Program at the Canadian Institute for Advanced Research, a Professor of Psychological Science at University of California, Irvine, and a Research Professor at Duke University.

Stephen Schueller is a clinical psychologist and mental health service researcher who focuses on using technology to expand access to and improve the accessibility of mental health services. He is an Assistant Professor of Psychological Science at the University of California, Irvine, and an Adjunct Assistant Professor of Preventive Medicine at Northwestern University, Feinberg School of Medicine.

Share article on social media or email:

View post:
Teens' technology use and mental health: New report from the Connected Learning Lab provides insight into Youth Connections for Wellbeing - PR Web

Posted in Integrative Medicine | Comments Off on Teens’ technology use and mental health: New report from the Connected Learning Lab provides insight into Youth Connections for Wellbeing – PR Web

Regenerative Medicine: The Future of Medicine is Here but Not Without Challenges | Infiniti Research – Business Wire

Posted: June 23, 2020 at 5:54 pm

LONDON--(BUSINESS WIRE)--Infiniti Research is the world's leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed to connect your organizations goals with global opportunities. Today's competitive business environment demands in-depth, accurate, and reliable business information to ensure that companies gain a strong foothold in domestic or foreign markets. Our global industry specialist teams ensure the international consistency of our research, enabling powerful access to the real story behind market changes. Request a free brochure for more insights into our solutions portfolio.

Regenerative medicine is currently the hive of innovation in modern science with far-reaching benefits for big pharma, healthcare systems, and patient outcomes. The rapid pace of development is expected in the US regenerative medicine market over the next decade. Some of the key factors fueling demand include the increasing investments in R&D activities and the rising incidence of chronic diseases in the country. Leading vendors have enhanced their R&D investments to develop innovative medical therapies, which is driving the overall growth of the market. Furthermore, M&A and strategic alliances among vendors will have a significant impact on the overall market growth and innovation. Nevertheless, the actual delivery of regenerative medicines has proven to be rather challenging with several roadblocks to commercially viable therapies that are capable of catering to unmet clinical needs.

The promise of regenerative medicines requires an innovative look at the complete product lifecycle, including the development of an efficient distribution network. Planning to venture into this space? Request a free proposal for comprehensive insights about the market.

Experts at Infiniti Research outline some of the most relevant and pressing manufacturing challenges in regenerative medicine products:

Manufacturing expense: Cell therapy manufacturing processes are generally highly expensive. Scaling up from limited laboratory facilities to automated systems for bulk production will largely be based on cost, therefore impeccable financial and time planning become vital.

Design quality: In the case of automation, robots manually reproduce the existing inefficient manual processes due to which the products are often based on obsolete technologies. As a result, the manufacture of regenerative medicines sometimes misses the opportunity to improve their quality by innovating process design.

Biomaterials challenges: Challenges relating to biomaterials are mostly concerned with their selection than the manufacturing process. The trends in material selection will eventually have a major impact on the manufacturing process.

Supply chain challenges: The clinical supply chains required to deliver regenerative medicines therapies are arguably the most complex the industry has seen so far, even more so than for biologic medicine.

Read the complete article for comprehensive insights on the key regenerative medicine manufacturing challenges.

The personalization and unique requirements of regenerative medicines require manufacturers to provide an increased focus on the precision and accuracy of processes. Get in touch with an industry expert from Infiniti research to identify gaps in your existing processes and bridge them with viable business strategies.

About Infiniti Research

Established in 2003, Infiniti Research is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies. To know more, visit: https://www.infinitiresearch.com/about-us

Read the original post:
Regenerative Medicine: The Future of Medicine is Here but Not Without Challenges | Infiniti Research - Business Wire

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine: The Future of Medicine is Here but Not Without Challenges | Infiniti Research – Business Wire

Global Regenerative Medicine Market (2020 to 2024) – Size & Forecast with Impact Analysis of COVID-19 – ResearchAndMarkets.com – Business Wire

Posted: June 23, 2020 at 5:54 pm

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

This report provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs of the human body to cure the problem caused by disease or injury. The treatment fortifies the human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimer's, diabetes, Parkinson's, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Market Dynamics

Growth Drivers

Challenges

Market Trends

Companies Profiled

For more information about this report visit https://www.researchandmarkets.com/r/ufteqn

See more here:
Global Regenerative Medicine Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire

Posted in Regenerative Medicine | Comments Off on Global Regenerative Medicine Market (2020 to 2024) – Size & Forecast with Impact Analysis of COVID-19 – ResearchAndMarkets.com – Business Wire

Regenerative Medicine Market to Record a Robust Growth Rate for the COVID-19 Period – Cole of Duty

Posted: June 23, 2020 at 5:54 pm

Overview: Regenerative medicine is an interdisciplinary field that applies life science and engineering principles for the regeneration or repair of injured/diseased tissues or organs resulting from various causes including, disease, defects, trauma and aging. The field includes the generation and use of tissue engineering, therapeutic stem cells and the production of artificial organs. It also allows scientists to grow organs or tissues in the lab and implant them in the body safely when the body fails to heal itself. Notably, it has great potential to solve the problem of organ shortage.

Request For Report [emailprotected]https://www.trendsmarketresearch.com/report/sample/9918

According to the estimation of World Health Organization, there is an increasing prevalence of diabetes among adults over the age of 18 years, that has increased to 8.5% in 2014 compared to 4.5% in 1980 across the globe. As per the estimation of Arthritis Foundation, the number of people expected to be diagnosed from arthritis will be more than 78 million, by 2040.

The market for regenerative medicine is driven by increasing prevalence of neuronal disease, cancer and genetic disease, emerging application of regenerative medicine, and advancement in technology. Huge number of ongoing clinical trails and strong product pipeline are providing market growth oppurtunity. High cost of the treatment, regulatory issues and ethical issuesare hampering the market growth.

Market Analysis: The Global Regenerative Medicine market is estimated to witness a CAGR of 16.6% during the forecast period 20182024. The global market is analyzed based on three segments Therapy, Application and regions.

Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global regenerative medicine market, followed by Europe. Asia-Pacific region is expected to have the fastest growth rate with the market growth centered at Japan, China and India. This is mainly due to increasing funding in healthcare research, rising research activities, growing patient pool, flexible regulatory environment for clinical trials, and rising healthcare expenditure.

Get Complete TOC with Tables and [emailprotected]https://www.trendsmarketresearch.com/report/discount/9918

Therapy Analysis:Immunotherapy occupied major market share of global regenerative medicine market in 2017, and is expected to remain same during the forecasted period. Increasing product approvals, emerging technological advancements in cell and gene therapy, flexible regulatory for stem cell based research, and growing awareness regarding the benefits of stem cell therapies.

Application Analysis: The market by application is segmented into cancer, central nervous system, orthopedic and musculoskeletal, diabetes, dermatology, cardiovascular and others. Among various application, dermatology occupied the largest share in 2017 and cancer segment is expected to grow at fastest rate during the forecasted period. Growing aging population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.

Key Players: Allergan plc, Integra lifesciences, Mimedx Group, Inc., Medtronic plc, Organogenesis Inc., Zimmer Biomet, Acelity L.P. Inc., Nuvasive, Inc., Stryker Corporation, Japan Tissue Engineering Co., Ltd. (Fujifilm Holdings Corporation subsidiary), Osiris Therapeutics, Inc., Vericel Corporationand other predominate and niche players.

Competitive Analysis: Currently dermatology segment dominates the global regenerative medicine segment. A lot of researches are going on cancer, CNS, cardiovascular, orthopedic & musculoskeletal applications. The increasing importance of regenerative medicine has resulted in the launch of new products and also increased acquisition, approvals, funding to develop new product.

For instance, in August 2017, Tissue Regenix Group plc completed the acquisition of acquisition of CellRight Technologies, an US based specialist in regenerative osteoinductive bone scaffolds. In April 2018, Roche acquired a program named Inception 5, focused on regenerative therapies for multiple sclerosis. In May 2018, Novartis received second FDA approval for Kymriah, CAR-T cell therapy for B-cell acute lymphoblastic leukemia (ALL)

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/9918

Benefits: The report provides complete details about the usage and adoption rate of regenerative medicine in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical players initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

More here:
Regenerative Medicine Market to Record a Robust Growth Rate for the COVID-19 Period - Cole of Duty

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine Market to Record a Robust Growth Rate for the COVID-19 Period – Cole of Duty

Graham Company and Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for Employers – PRNewswire

Posted: June 23, 2020 at 5:54 pm

PHILADELPHIA, June 23, 2020 /PRNewswire/ --Graham Company, one of the country's largest insurance brokerages, today announced a new partnership with Regenexx, a network of leading interventional orthopedics clinics. The partnership gives Graham Company's self-insured clients the option to offer alternative non-surgical orthopedic treatment methods, provided by Regenexx through its expansive network of physicians, as a benefit enhancement for employees. In addition, the partnership will help Graham Company's clients control and reduce overall costs of orthopedic surgery procedures for employees.

According to data from Regenexx, its procedures have effectively intervened on 70% of elective orthopedic injuries and conditions where surgery was previously the only solution.* Regenexx offers a unique approach to treating orthopedic injuries non-surgically through stem cell therapy and other regenerative medicine. Procedures performed by Regenexx's specially trained physician network involve injections of custom orthobiologics, derived from the patient's own cells and natural healing agents, to treat approximately 40 orthopedic conditions. This interventional approach enables employers to save up to 70% of orthopedic costs by reducing the number of unnecessary surgeries performed annually.

"At Graham Company, we are committed to identifying solutions to help our clients control escalating health care costs while also enhancing their benefits offerings for employees," said Debra Montella, Graham Company's Vice President of the Employee Benefits Division. "Through this partnership with Regenexx, we are now able to present our self-insured clients with a unique approach that is transforming orthopedic care and driving down costs associated with surgical procedures."

This partnership also benefits the employees of clients with self-funded plans, providing them with alternative non-surgical treatment options to address orthopedic injuries or conditions. Regenexx company data found that when employees are given the choice between an invasive orthopedic surgery or its non-invasive procedure to treat orthopedic conditions, employees chose Regenexx's procedure a majority of the time. Compared to traditional orthopedic surgeries, Regenexx procedures require less downtime for patients and are considered less costly, less invasive and less risky.

"Regenexx is looking forward to expanding our mission of producing the best possible patient outcomes for Graham Company and their clients through our innovative alternative to orthopedic surgery," said Regenexx CEO Jason Hellickson. "Our patented regenerative approach to treating common orthopedic conditions is transforming the care pathway of an orthopedic patient who can now avoid a surgical encounter with less risk and less downtime."

*This data applies only to elective orthopedic surgery without fracture-related care and acute care trauma.

About Graham CompanyGraham Company is one of the largest insurance and employee benefits brokers in the country, committed to enhancing employee safety and business viability through an action-oriented approach to risk management. In business for nearly 60 years, Graham Company designs customized and effective property and casualty, surety and employee benefits programs for its clients to protect employees and prevent losses. With offices in Philadelphia, New York City and Washington, D.C., Graham Company became 100 percent employee-owned through an employee stock ownership plan in 2017. Through its innovative insurance and safety training programs, Graham Company is redefining what it means to be an insurance broker. To learn more, visit http://www.grahamco.com.

GRAHAM COMPANY IS AN INSURANCE BROKER AND NOT A MEDICAL CARE PROVIDER. ANY QUESTIONS CONCERNING THIS PROCEDURE SHOULD BE REFERRED TO REGENEXX OR YOUR MEDICAL CARE PROVIDER.

About RegenexxRegenexx is a nationwide network of physicians who practice Interventional Orthopedics, a new specialty that focuses on using the most advanced regenerative protocols available as an alternative to many orthopedic surgeries. Regenexx has published roughly half of the research worldwide on the use of orthobiologics for treating orthopedic injuries, and our patented treatment lab-processing and treatment protocols allow us to achieve unmatched results. Our procedures use your body's natural healing agents including blood platelets and bone marrow concentrate to repair damaged bone, muscle, cartilage, tendons and ligaments. We believe in educating patients, offering options and encouraging people to take an active role in their own treatment. For more information on Regenexx Corporate, visit http://www.regenexxcorporate.com or call 888-547-6667. For more information on the Regenexx procedures, visit http://www.regenexx.com.

SOURCE Regenexx

http://www.regenexx.com

The rest is here:
Graham Company and Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for Employers - PRNewswire

Posted in Regenerative Medicine | Comments Off on Graham Company and Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for Employers – PRNewswire

Regenerative Medicine Market Key Trends, Growth, Share, Size, Analysis and Forecast to 2023 – 3rd Watch News

Posted: June 23, 2020 at 5:54 pm

Premium market insights delivers well-researched industry-wide information on the Regenerative Medicine market. It studies the markets essential aspects such as top participants, expansion strategies, business models, and other market features to gain improved market insights. Additionally, it focuses on the latest advancements in the sector and technological development, executive tools, and tactics that can enhance the performance of the sectors.

Request Sample Copy of Regenerative Medicine Market at: https://www.premiummarketinsights.com/sample/AMR00013825

Scope of the Report

The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines repair, replace, and regenerate tissues and organs affected due to injury, disease, or natural ageing process. These medicines help restore the functionality of cells & tissues and are applicable in numerous degenerative disorders such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. Researchers focus on developing technologies based on biologics, genes, somatic as well as stem cells. Stem cells are capable of proliferation and differentiation and hence, are critical in this field.

The major factors that boost the market growth include technological advancements in tissue and organ regeneration, increase in prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, rise in degenerative diseases and shortage of organs for transplantation are expected to fuel the growth of the market. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened numerous growth avenues for the regenerative medicines market. However, stringent regulatory barriers and high cost of the treatment are likely to hinder the market growth.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.premiummarketinsights.com/discount/AMR00013825

Top Key Players:

KEY MARKET BENEFITS FOR STAKEHOLDERS

This report offers a detailed quantitative analysis of the market trends from 2016 to 2023 to identify the prevailing opportunities.

The market estimations provided in this report are based on a comprehensive analysis of the key developments in the industry.

An in-depth analysis based on geography facilitates the study of the regional market to assist in strategic business planning.

The development strategies adopted by the key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Product Type

Cell Therapy

Gene Therapy

Tissue Engineering

Small Molecule & Biologic

By Material

Synthetic Material

Biodegradable Synthetic Polymer

Scaffold

Artificial Vascular Graft Material

Hydrogel Material

Biologically Derived Material

Interested in purchasing this Report? Click here @ https://www.premiummarketinsights.com/inquiry/AMR00013825

Geographically, this report focuses on product sales, value, market share, and growth opportunity in key regions such as United States, Europe, China, Japan, Southeast Asia, and India.

About Premium market insights:

Premiummarketinsights.comis a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact US:

Sameer Joshi Call: US: +1-646-491-9876, Apac: +912067274191Email: [emailprotected]

Read this article:
Regenerative Medicine Market Key Trends, Growth, Share, Size, Analysis and Forecast to 2023 - 3rd Watch News

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine Market Key Trends, Growth, Share, Size, Analysis and Forecast to 2023 – 3rd Watch News

AVITA Medical Limited Proposed Redomiciliation to the United States of America – Court Approves Scheme of Arrangement – Business Wire

Posted: June 23, 2020 at 5:54 pm

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical Limited ACN 058 466 523 (Company) is pleased to announce that the Federal Court of Australia (Court) has today approved the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries (Avita Group) from Australia to the United States of America (Scheme), under which AVITA Therapeutics, Inc. ARBN 641 288 155 (Avita US), a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.

The Company expects to lodge a copy of the Court orders with the Australian Securities and Investments Commission (ASIC) tomorrow (Tuesday, 23 June 2020). Once the orders are registered with ASIC, the Scheme will become effective.

The Companys shares will be suspended from trading on the ASX from close of trading on Tuesday, 23 June 2020.

The expected timetable for implementation of the Scheme is set out below:

Event

Indicative Date

Effective Date for the Scheme

Last day of trading of the Companys shares on the ASX

23 June 2020

Listing of Avita US on the ASX

Trading of Avita US Chess Depositary Interests (CDIs) commences on the ASX on a deferred settlement basis

24 June 2020

Record Date (for determining the entitlements of shareholders of the Company to Avita US shares or Avita US CDIs)

7.00pm (AEST) on 25 June 2020

Last day of trading of the Companys American Depositary Shares (ADSs) on NASDAQ

Last day of trading of Avita US CDIs on the ASX on a deferred settlement basis

29 June 2020

Implementation Date

Issue of Avita US shares or Avita US CDIs to eligible shareholders of the Company

29 June 2020

Listing of Avita US on NASDAQ

Trading of Avita US Shares commences on NASDAQ

Promptly following the Implementation Date

Trading of Avita US CDIs commences on the ASX on a normal basis

30 June 2020

Any changes to the above dates will be announced to the ASX and NASDAQ and via news release, and will also be notified on the Companys website (www.avitamedical.com).

Authorised for release by the Chief Financial Officer of AVITA Medical Limited.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This announcement includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this announcement include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this announcement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this announcement. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this announcement speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

See the article here:
AVITA Medical Limited Proposed Redomiciliation to the United States of America - Court Approves Scheme of Arrangement - Business Wire

Posted in Regenerative Medicine | Comments Off on AVITA Medical Limited Proposed Redomiciliation to the United States of America – Court Approves Scheme of Arrangement – Business Wire

Practices and Pitfalls of 3D Printing for COVID-19 – Advanced Manufacturing

Posted: June 23, 2020 at 5:54 pm

By now, most of us in the manufacturing world are familiar with the steady stream of news describing organizations, large and small, providing medical equipment using 3D printers. Face masks, face shields, swabs, and parts for ventilators are the most commonand neededas the frontline medical community struggles to heal patients while protecting themselves. What could be simpler than to create a design, prep the data, ship it to a printer and send the finished part to a happy user or manufacturer?

It is not as simple as it sounds.

There are literally hundreds of 3D printing designs to support the current COVID-19 response. Some work, others dont. Some look great but do not work, explained Dr. Jenny Chen, M.D., founder and CEO of 3DHEALS, a company focusing on education and industrial research in bioprinting, regenerative medicine, and healthcare applications using 3D printing. She was a moderator for a webinar panel titled 3D Printing Design for COVID-19, presented April 22.

Some of the most relevant highlights from the 90-minute webinar were discussions about liability, best choice of materials, and dealing with material shortages as demand spikes for the raw materials needed to make the products that are in such high demand.

In March, four people started a non-profit group called MAKE4COVID and [as of April 22] we are over 2,000 people making needed personal protective equipment (PPE) for the greater Colorado area, said Nicholas Jacobson in the webinar. He is an architect and designer focused on biomedical 3D printing. MAKE4COVID is a coalition formed by the maker community, with small providers as well as larger companies.

Jacobson stressed the need to work directly with surgeons using PPE to develop the best designs possible. We had a trauma surgeon who literally flipped our design [for a face shield] upside down to make it work better for her, he said. We had high hopes when we started, but we would come up with a design and [the sources for] materials dried up, he said, a caution echoed by others in the webinar. He explained how they made do with substitutes, constantly shifting designs to accommodate the materials they could actually get.

He also shared concerns about liability. Face shields were easy because there was no liability attached, at least in Colorado, he said. But, as we get into producing medical devices, the territory gets a lot trickier. He noticed that there was much initial skepticism of taking equipment from such a coalition, until the pandemic progressed and the need became greater. Still, liability is a real concern for the future.

Beyond face shields, MAKE4COVID also went through a process of designing face masks, which as of April 22 were in production. Again, as in face shields, Jacobson stressed it was a process that required input from end users to create an acceptable face mask design.

Dr. Kevin Yoder, D.D.S., is a practicing dentist who also provides software for dentists to employ 3D printers in their practices. He stressed the need to use biocompatible resins from 3D printers. If you are using 3D printing for face masks and other PPE, one should ask if there is any harm in doing that, such as allergic reactions, he said. Using biocompatible resins would reduce that, among other considerations. He also stressed that when using FDM for PPE, avoid using ABS since it produces a harmful off-gas. The FDM materials he recommended were TPU, PLA and PETG.

Yoder also noted that even among the 3D-printed masks they were one-size-fits-all designs. Adapting designs to the unique anatomy [of patients] and creating one-off designs is what dentists do all the time, he said. In response, he adapted his dental software to create MeshMask, a free and semi-automated software tool to create a custom-fitted mask based on 3D face scans.

As expected, it is not just in the U.S. that people are finding source materials difficult to get. If you are looking for straight plastic PETG right now, you will have to wait at least 15 weeks, said Dr. Stephanie Willerth. She has been working with a group in British Columbia using an open-source approach to 3D printing for PPE. She has the technical credentials, holding a Canada Research Chair in Biomedical Engineering at the University of Victoria, Canada with dual appointments in the Department of Mechanical Engineering and the Division of Medical Sciences as a Full Professor.

By converting what had been her biomedical laboratory into a temporary facility for inspecting and sterilizing the parts, the lab has been able to ship out 100 to 200 face shields per day for use in B.C. We did consult with the Health Canada authorities to ensure our designs were suitable and we did have some disclaimers on our packaging, she said.

She expressed a sentiment most ad hoc providers can relate to. A month ago we werent doing this and now we are making large quantities and shipping them every day, she said.

As Dr. Chen noted in the conversation afterwards, there is a possibility that liability can be an issue after all of this is over; the risk is not zero. However, if you have gone through various processes to vet your design, vet your final manufactured product, you have tried your best, and demonstrated a process or obtained your design from an official website, the risk may be decreased.

To listen and watch the entire webinar go to: https://3dheals.com/3d-printing-design-for-covid-19-show-notes-and-recordings

To learn more about 3DHEALS, go to https://3dheals.com/

Read this article:
Practices and Pitfalls of 3D Printing for COVID-19 - Advanced Manufacturing

Posted in Regenerative Medicine | Comments Off on Practices and Pitfalls of 3D Printing for COVID-19 – Advanced Manufacturing

Page 959«..1020..958959960961..970980..»